Recursion, a drug discovery startup out of Salt Lake City, Utah has announced a $60 million Series B round, led by Data Collective (DCVC). Recursion started out in 2014 on a mission to identify 100 new treatments in 10 years. That’s a lofty goal, considering the discovery for just one drug can traditionally take decades and tens of millions of dollars, with a high rate of failure… Read More

Source: New feed